{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:41:46Z","timestamp":1784619706042,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.phrs.2020.104717","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:44:43Z","timestamp":1582245883000},"page":"104717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer"],"prefix":"10.1016","volume":"155","author":[{"given":"Yu-Hang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Dong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Biao","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Jun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.104717_bib0005","first-page":"1","article-title":"A review of the evolution of systemic chemotherapy in the management of colorectal cancer","volume":"14","author":"Gustavsson","year":"2015","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.phrs.2020.104717_bib0010","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMra040958","article-title":"Systemic therapy for colorectal cancer","volume":"352","author":"Meyerhardt","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.104717_bib0015","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/annonc\/mdh264","article-title":"5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers","volume":"15","author":"Noordhuis","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2020.104717_bib0020","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2020.104717_bib0025","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.taap.2004.08.018","article-title":"5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice","volume":"203","author":"Innocenti","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.phrs.2020.104717_bib0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","article-title":"Clinical pharmacology of 5-fluorouracil","volume":"16","author":"Diasio","year":"1989","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2020.104717_bib0035","first-page":"4116","article-title":"Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil","volume":"9","author":"Kornmann","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2020.104717_bib0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FPC.0000000000000197","article-title":"Association between DPYD c.1129-5923 C&G\/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)","volume":"26","author":"Lee","year":"2016","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.phrs.2020.104717_bib0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/gutjnl-2013-306571","article-title":"A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS","volume":"64","author":"Rosmarin","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.104717_bib0050","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/clpt.2013.172","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing","volume":"94","author":"Caudle","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.104717_bib0055","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/0929867053363432","article-title":"Novel chemical strategies for thymidylate synthase inhibition","volume":"12","author":"Gmeiner","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2020.104717_bib0060","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.1994.12.10.2035","article-title":"Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil","volume":"12","author":"Peters","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2020.104717_bib0065","first-page":"748","article-title":"Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts","volume":"78","author":"Tatsumi","year":"1987","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.phrs.2020.104717_bib0070","first-page":"2000","article-title":"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug","volume":"5","author":"Hirata","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2020.104717_bib0075","first-page":"1765","article-title":"Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis","volume":"112","author":"Nakamura","year":"2008","journal-title":"Cancer-Am Cancer Soc"},{"key":"10.1016\/j.phrs.2020.104717_bib0080","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1158\/0008-5472.CAN-16-1306","article-title":"Histone H3K27 trimethylation modulates 5-Fluorouracil resistance by inhibiting PU.1 binding to the DPYD promoter","volume":"76","author":"Wu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2020.104717_bib0085","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fphar.2017.00296","article-title":"Sphingosine 1-Phosphate Receptors: Do They Have a Therapeutic Potential in Cardiac Fibrosis?","volume":"8","author":"Vestri","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2020.104717_bib0090","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.104717_bib0095","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.104717_bib0100","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ana.25219","article-title":"Permeability of the blood-brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis","volume":"83","author":"Cramer","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2020.104717_bib0105","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nn.3728","article-title":"Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory","volume":"17","author":"Hait","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.phrs.2020.104717_bib0110","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1182\/blood-2005-07-2628","article-title":"Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720","volume":"107","author":"Zemann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2020.104717_bib0115","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ana.22426","article-title":"Mechanisms of fingolimod\u2019s efficacy and adverse effects in multiple sclerosis","volume":"69","author":"Cohen","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2020.104717_bib0120","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1073\/pnas.1615413114","article-title":"Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation","volume":"114","author":"Rothhammer","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2020.104717_bib0125","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.3892\/or.2013.2765","article-title":"FTY720 for cancer therapy (Review)","volume":"30","author":"Zhang","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2020.104717_bib0130","first-page":"22","article-title":"Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis","volume":"16","author":"Pouzol","year":"2019","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.phrs.2020.104717_bib0135","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.phrs.2020.104717_bib0140","first-page":"625","article-title":"A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil","volume":"31","author":"Saif","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phrs.2020.104717_bib0145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fphar.2011.00026","article-title":"Selectivity and specificity of sphingosine 1-phosphate receptor ligands: \u201coff-targets\u201d or complex pharmacology?","volume":"2","author":"Pyne","year":"2011","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2020.104717_bib0150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-4347(00)00377-7","article-title":"Determination of 5-fluorouracil in environmental samples by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection","volume":"750","author":"Micoli","year":"2001","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."}],"updated-by":[{"DOI":"10.1016\/j.phrs.2020.104834","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000}}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819324934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819324934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:07:55Z","timestamp":1760911675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819324934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":30,"alternative-id":["S1043661819324934"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104717","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104717"}}